Primary Myelofibrosis
139
25
36
66
Key Insights
Highlights
Success Rate
74% trial completion
Published Results
55 trials with published results (40%)
Research Maturity
66 completed trials (47% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
16.5%
23 terminated out of 139 trials
74.2%
-12.3% vs benchmark
13%
18 trials in Phase 3/4
83%
55 of 66 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 66 completed trials
Clinical Trials (139)
Study of Canakinumab in Patients With Myelofibrosis
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Decitabine in Treating Patients With Myelofibrosis
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Extended Access of Momelotinib in Adults With Myelofibrosis
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
Fedratinib in Combination With Nivolumab
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
Registry Platform Myelofibrosis and Anemia
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
CINC424A2X01B Rollover Protocol
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)